Find Tesamorelin Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 901758-09-6, Th9507, Unii-lgw5h38ve3, Tesamorelin acetate [usan], Lgw5h38ve3, (3e)-hex-3-enoylsomatoliberin (human) acetate (salt)
Molecular Formula
C223H370N72O69S
Molecular Weight
5196  g/mol
InChI Key
LAJZPRPPHHRDIK-BCEXXFMNSA-N

Tesamorelin Acetate
1 2D Structure

Tesamorelin Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
acetic acid;(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
2.1.2 InChI
InChI=1S/C221H366N72O67S.C2H4O2/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5;1-2(3)4/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249);1H3,(H,3,4)/b30-28+;/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-;/m0./s1
2.1.3 InChI Key
LAJZPRPPHHRDIK-BCEXXFMNSA-N
2.1.4 Canonical SMILES
CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N.CC(=O)O
2.1.5 Isomeric SMILES
CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N.CC(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Egrifta

2. Tesamorelin

3. Th-9507

4. Th9507

2.2.2 Depositor-Supplied Synonyms

1. 901758-09-6

2. Th9507

3. Unii-lgw5h38ve3

4. Tesamorelin Acetate [usan]

5. Lgw5h38ve3

6. (3e)-hex-3-enoylsomatoliberin (human) Acetate (salt)

2.2.3 Other Synonyms

1. Tesamorelin

2. Egrifta

2.3 Create Date
2009-08-20
3 Chemical and Physical Properties
Molecular Weight 5196 g/mol
Molecular Formula C223H370N72O69S
Hydrogen Bond Donor Count84
Hydrogen Bond Acceptor Count78
Rotatable Bond Count187
Exact Mass5194.7444797 g/mol
Monoisotopic Mass5192.7377700 g/mol
Topological Polar Surface Area2400 Ų
Heavy Atom Count365
Formal Charge0
Complexity12800
Isotope Atom Count0
Defined Atom Stereocenter Count44
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Growth Substances

Signal molecules that are involved in the control of cell growth and differentiation. (See all compounds classified as Growth Substances.)


API SUPPLIERS

read-more
read-more

01

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Bachem Americas, Inc.

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Flag Switzerland
Digital Content Digital Content

TESAMORELIN ACETATE

NDC Package Code : 52416-107

Start Marketing Date : 2010-11-10

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

Bachem company banner

02

Pharma Manufacturing 2024
Not Confirmed
arrow
arrow
Pharma Manufacturing 2024
Not Confirmed

TESAMORELIN ACETATE

NDC Package Code : 73212-014

Start Marketing Date : 2020-08-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

03

Pharma Manufacturing 2024
Not Confirmed
arrow
arrow
Pharma Manufacturing 2024
Not Confirmed

TESAMORELIN ACETATE

NDC Package Code : 71052-520

Start Marketing Date : 2019-09-24

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

04

Pharma Manufacturing 2024
Not Confirmed
arrow
arrow
Pharma Manufacturing 2024
Not Confirmed

TESAMORELIN ACETATE

NDC Package Code : 76112-711

Start Marketing Date : 2014-07-14

End Marketing Date : 2024-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

05

Hangzhou Sinodo Pharm Technology Co...

Country
Pharma Manufacturing 2024
Not Confirmed
arrow

Hangzhou Sinodo Pharm Technology Co...

Country
arrow
Pharma Manufacturing 2024
Not Confirmed

TESAMORELIN ACETATE

NDC Package Code : 82907-987

Start Marketing Date : 2024-08-06

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Tesamorelin Acetate

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
LGM Pharma CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Egrifta

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2024

blank

01

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

Brand Name : Egrifta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 24, 2024

blank

Details:

Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Egrifta

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2024

blank

02

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

Brand Name : Egrifta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 23, 2024

blank

Details:

EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Egrifta MDV

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 04, 2023

blank

03

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Brand Name : Egrifta MDV

Molecule Type : Large molecule

Upfront Cash : Not Applicable

October 04, 2023

blank

Details:

EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Dermatology Brand Name: Egrifta F8

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 25, 2023

blank

04

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Brand Name : Egrifta F8

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 25, 2023

blank

Details:

TH9507 (tesamorelin) stimulates growth hormone secretion (GHRH), and subsequently increases IGF-1 and IGFBP-3 levels. GHRH is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: EGRIFTA SV

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 22, 2023

blank

05

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : TH9507 (tesamorelin) stimulates growth hormone secretion (GHRH), and subsequently increases IGF-1 and IGFBP-3 levels. GHRH is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Brand Name : EGRIFTA SV

Molecule Type : Peptide

Upfront Cash : Not Applicable

February 22, 2023

blank

Details:

EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Dermatology Brand Name: Egrifta SV

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: World Orphan Drug Alliance

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 05, 2023

blank

06

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Brand Name : Egrifta SV

Molecule Type : Large molecule

Upfront Cash : Undisclosed

January 05, 2023

blank

Details:

The priorities include the advancement of the clinical oncology pipeline, which is currently in a larger Phase 1b basket study, and the rapid growth of our existing marketed brands, EGRIFTA SV® and Trogarzo®.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Dermatology Brand Name: Egrifta SV

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Marathon Asset Management

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing July 13, 2022

blank

07

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : The priorities include the advancement of the clinical oncology pipeline, which is currently in a larger Phase 1b basket study, and the rapid growth of our existing marketed brands, EGRIFTA SV® and Trogarzo®.

Brand Name : Egrifta SV

Molecule Type : Peptide

Upfront Cash : Undisclosed

July 13, 2022

blank

Details:

The Phase 3 clinical trial will be a multicenter, double-blind, placebo-controlled two-part study to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Egrifta

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2021

blank

08

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : The Phase 3 clinical trial will be a multicenter, double-blind, placebo-controlled two-part study to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis.

Brand Name : Egrifta

Molecule Type : Peptide

Upfront Cash : Not Applicable

July 15, 2021

blank

Details:

Oral presentation includes data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Tesamorelin F8

Study Phase: Phase IIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 06, 2020

blank

09

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : Oral presentation includes data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).

Brand Name : Tesamorelin F8

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 06, 2020

blank

Details:

The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.


Lead Product(s): Tesamorelin Acetate

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: F8

Study Phase: Phase IIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 13, 2020

blank

10

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.

Brand Name : F8

Molecule Type : Large molecule

Upfront Cash : Not Applicable

October 13, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG PEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 100 UNITS/ML

Packaging :

Approval Date :

Application Number : 20563

Regulatory Info :

Registration Country : USA

blank

02

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG KWIKPEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 100 UNITS/ML

Packaging :

Approval Date :

Application Number : 20563

Regulatory Info :

Registration Country : USA

blank

03

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG KWIKPEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 200UNITS/ML

Packaging :

Approval Date :

Application Number : 20563

Regulatory Info :

Registration Country : USA

blank

04

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG TEMPO PEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 100UNITS/ML

Packaging :

Approval Date :

Application Number : 20563

Regulatory Info :

Registration Country : USA

blank

05

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG MIX 75/25 KWIKPEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 75 UNITS/ML;25 UNITS/ML

Packaging :

Approval Date :

Application Number : 21017

Regulatory Info :

Registration Country : USA

blank

06

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG MIX 75/25 PEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 75 UNITS/ML;25 UNITS/ML

Packaging :

Approval Date :

Application Number : 21017

Regulatory Info :

Registration Country : USA

blank

07

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG MIX 50/50

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 50 UNITS/ML;50 UNITS/ML

Packaging :

Approval Date :

Application Number : 21018

Regulatory Info :

Registration Country : USA

blank

08

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG MIX 50/50 KWIKPEN

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 50 UNITS/ML;50 UNITS/ML

Packaging :

Approval Date :

Application Number : 21018

Regulatory Info :

Registration Country : USA

blank

09

Eli Lilly

U.S.A
euroPLX 86 Munich
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

INSULIN LISPRO RECOMBINANT

Brand Name : HUMALOG KWIKPEN

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 200 UNITS/ML

Packaging :

Approval Date :

Application Number : 205747

Regulatory Info :

Registration Country : USA

blank

10

euroPLX 86 Munich
Not Confirmed
arrow
arrow
euroPLX 86 Munich
Not Confirmed

TESAMORELIN ACETATE

Brand Name : EGRIFTA

Dosage Form : POWDER;SUBCUTANEOUS

Dosage Strength : EQ 1MG BASE/VIAL

Packaging :

Approval Date :

Application Number : 22505

Regulatory Info :

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty